Skip to main content
SpringerLink
Log in

Hallucinations in Neurological Disorders

  • Chapter
  • First Online:
Hallucinations in Psychoses and Affective Disorders

  • 738 Accesses

Abstract

Hallucinations are present in many nonpsychiatric subjects. Indeed, these false perceptions are frequently observed in degenerative and non-degenerative neurological disorders. In this chapter, we aim to describe the phenomenology, pathogenesis, and available therapies for hallucinations in these neurological conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aleman A, Larøi F. Hallucinations: the science of idiosyncratic perception. Psychiatric Services. 2008;60.10.1037/11751-000.

    Google Scholar 

  2. Rasmussen T, Penfield W. Further studies of the sensory and motor cerebral cortex of man. Fed Proc. 1947;6(2):452–60.

    PubMed  CAS  Google Scholar 

  3. Kompanje EJ. ‘The devil lay upon her and held her down’. Hypnagogic hallucinations and sleep paralysis described by the Dutch physician Isbrand van Diemerbroeck (1609–1674) in 1664. J Sleep Res. 2008;17(4):464–7.

    Article  PubMed  CAS  Google Scholar 

  4. Waters F, Blom JD, Dang-Vu TT, Cheyne AJ, Alderson-Day B, Woodruff P, et al. What is the link between hallucinations, dreams, and hypnagogic-hypnopompic experiences? Schizophr Bull. 2016;42(5):1098–109.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dahmen N, Kasten M. REM-associated hallucinations and sleep paralysis are dependent on body posture. J Neurol. 2001;248(5):423–4.

    Article  PubMed  CAS  Google Scholar 

  6. Dahmen N, Kasten M, Muller MJ, Mittag K. Frequency and dependence on body posture of hallucinations and sleep paralysis in a community sample. J Sleep Res. 2002;11(2):179–80.

    Article  PubMed  Google Scholar 

  7. Cheyne JA, Newby-Clark IR, Rueffer SD. Relations among hypnagogic and hypnopompic experiences associated with sleep paralysis. J Sleep Res. 1999;8(4):313–7.

    Article  PubMed  CAS  Google Scholar 

  8. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain. 1998;121(Pt 10):1819–40.

    Article  PubMed  Google Scholar 

  9. Cheyne JA, Rueffer SD, Newby-Clark IR. Hypnagogic and hypnopompic hallucinations during sleep paralysis: neurological and cultural construction of the night-mare. Conscious Cogn. 1999;8(3):319–37.

    Article  PubMed  CAS  Google Scholar 

  10. McNally RJ, Clancy SA. Sleep paralysis, sexual abuse, and space alien abduction. Transcult Psychiatry. 2005;42(1):113–22.

    Article  PubMed  Google Scholar 

  11. Hishikawa Y, Nan'no H, Tachibana M, Furuya E, Koida H, Kaneko Z. The nature of sleep attack and other symptoms of narcolepsy. Electroencephalogr Clin Neurophysiol. 1968;24(1):1–10.

    Article  PubMed  CAS  Google Scholar 

  12. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology. 2000;55(2):281–8.

    Article  PubMed  CAS  Google Scholar 

  13. Fazio—Loeb. Neurologia. 2003.

    Google Scholar 

  14. Penney L, Galarneau D. Peduncular hallucinosis: a case report. Ochsner J. 2014;14(3):450–2.

    PubMed  PubMed Central  Google Scholar 

  15. Middleton FA, Strick PL. The temporal lobe is a target of output from the basal ganglia. Proc Natl Acad Sci U S A. 1996;93(16):8683–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Spiegel DR, Rivers J, Peglow S. A probable case of peduncular hallucinosis status postthalamic and cerebral peduncle cerebrovascular accident treated successfully with risperidone. J Neuropsychiatry Clin Neurosci. 2014;26(3):E42.

    Article  PubMed  Google Scholar 

  17. Cammaroto S, D’Aleo G, Smorto C, Bramanti P. Charles Bonnet syndrome. Funct Neurol. 2008;23(3):123–7.

    PubMed  Google Scholar 

  18. Griffiths TD. Musical hallucinosis in acquired deafness. Phenomenology and brain substrate. Brain. 2000;123(Pt 10):2065–76.

    Article  PubMed  Google Scholar 

  19. Lerario A, Ciammola A, Poletti B, Girotti F, Silani V. Charles Bonnet syndrome: two case reports and review of the literature. J Neurol. 2013;260(4):1180–6.

    Article  PubMed  Google Scholar 

  20. Golden EC, Josephs KA. Minds on replay: musical hallucinations and their relationship to neurological disease. Brain. 2015;138(Pt 12):3793–802.

    Article  PubMed  Google Scholar 

  21. EF C, Marchie A, Norris M. Musical and auditory hallucinations: a spectrum. Psychiatry Clin Neurosci. 2004;58(1):96–8.

    Article  Google Scholar 

  22. Abbott EJ, Connor GB, Artes PH, Abadi RV. Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome). Invest Ophthalmol Vis Sci. 2007;48(3):1416–23.

    Article  PubMed  Google Scholar 

  23. Pang L. Hallucinations experienced by visually impaired: Charles Bonnet syndrome. Optom Vis Sci. 2016;93(12):1466–78.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci. 1998;1(8):738–42.

    Article  PubMed  CAS  Google Scholar 

  25. Eysel UT, Schweigart G, Mittmann T, Eyding D, Qu Y, Vandesande F, et al. Reorganization in the visual cortex after retinal and cortical damage. Restor Neurol Neurosci. 1999;15(2-3):153–64.

    PubMed  CAS  Google Scholar 

  26. Santhouse AM, Howard RJ, Ffytche DH. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain. 2000;123(Pt 10):2055–64.

    Article  PubMed  Google Scholar 

  27. Cogan DG. Visual hallucinations as release phenomena. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1973;188(2):139–50.

    Article  PubMed  CAS  Google Scholar 

  28. Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J Neurol Neurosurg Psychiatry. 2002;73(5):535–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Ukai S, Yamamoto M, Tanaka M, Takeda M. Treatment of typical Charles Bonnet syndrome with donepezil. Int Clin Psychopharmacol. 2004;19(6):355–7.

    Article  PubMed  Google Scholar 

  30. Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet’s syndrome. Lancet. 1996;347(9004):794–7.

    Article  PubMed  CAS  Google Scholar 

  31. Eperjesi F, Akbarali N. Rehabilitation in Charles Bonnet syndrome: a review of treatment options. Clin Exp Optom. 2004;87(3):149–52.

    Article  PubMed  Google Scholar 

  32. Waters WE, O’Connor PJ. Prevalence of migraine. J Neurol Neurosurg Psychiatry. 1975;38(6):613–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med. 2002;346(4):257–70.

    Article  PubMed  CAS  Google Scholar 

  34. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain. 1996;119(Pt 2):355–61.

    Article  PubMed  Google Scholar 

  35. Spranger M, Spranger S, Schwab S, Benninger C, Dichgans M. Familial hemiplegic migraine with cerebellar ataxia and paroxysmal psychosis. Eur Neurol. 1999;41(3):150–2.

    Article  PubMed  CAS  Google Scholar 

  36. Todd J. The syndrome of Alice in Wonderland. Can Med Assoc J. 1955;73(9):701–4.

    PubMed  PubMed Central  CAS  Google Scholar 

  37. Blom JD. Alice in Wonderland syndrome: a systematic review. Neurol Clin Pract. 2016;6(3):259–70.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98(8):4687–92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Miller EE, Grosberg BM, Crystal SC, Robbins MS. Auditory hallucinations associated with migraine: case series and literature review. Cephalalgia. 2015;35(10):923–30.

    Article  PubMed  Google Scholar 

  40. Schreier HA. Auditory hallucinations in nonpsychotic children with affective syndromes and migraines: report of 13 cases. J Child Neurol. 1998;13(8):377–82.

    Article  PubMed  CAS  Google Scholar 

  41. Lippman CW. Certain hallucinations peculiar to migraine. J Nerv Ment Dis. 1952;116(4):346–51.

    Article  PubMed  CAS  Google Scholar 

  42. Fuller GN, Guiloff RJ. Migrainous olfactory hallucinations. J Neurol Neurosurg Psychiatry. 1987;50(12):1688–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Wolberg FL, Ziegler DK. Olfactory hallucination in migraine. Arch Neurol. 1982;39(6):382.

    Article  PubMed  CAS  Google Scholar 

  44. Morrison DP. Abnormal perceptual experiences in migraine. Cephalalgia. 1990;10(6):273–7.

    Article  PubMed  CAS  Google Scholar 

  45. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754–62.

    Article  PubMed  CAS  Google Scholar 

  46. Chang BS, Lowenstein DH. Epilepsy. N Engl J Med. 2003;349(13):1257–66.

    Article  PubMed  Google Scholar 

  47. Wieser HG. Depth recorded limbic seizures and psychopathology. Neurosci Biobehav Rev. 1983;7(3):427–40.

    Article  PubMed  CAS  Google Scholar 

  48. Chen C, Shih YH, Yen DJ, Lirng JF, Guo YC, Yu HY, et al. Olfactory auras in patients with temporal lobe epilepsy. Epilepsia. 2003;44(2):257–60.

    Article  PubMed  Google Scholar 

  49. Hausser-Hauw C, Bancaud J. Gustatory hallucinations in epileptic seizures. Electrophysiological, clinical and anatomical correlates. Brain. 1987;110(Pt 2):339–59.

    Article  PubMed  Google Scholar 

  50. Baldeweg T, Spence S, Hirsch SR, Gruzelier J. Gamma-band electroencephalographic oscillations in a patient with somatic hallucinations. Lancet. 1998;352(9128):620–1.

    Article  PubMed  CAS  Google Scholar 

  51. Panayiotopoulos CP. Elementary visual hallucinations, blindness, and headache in idiopathic occipital epilepsy: differentiation from migraine. J Neurol Neurosurg Psychiatry. 1999;66(4):536–40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Taylor I, Scheffer IE, Berkovic SF. Occipital epilepsies: identification of specific and newly recognized syndromes. Brain. 2003;126(Pt 4):753–69.

    Article  PubMed  Google Scholar 

  53. Salanova V, Andermann F, Olivier A, Rasmussen T, Quesney LF. Occipital lobe epilepsy: electroclinical manifestations, electrocorticography, cortical stimulation and outcome in 42 patients treated between 1930 and 1991. Surgery of occipital lobe epilepsy. Brain. 1992;115(Pt 6):1655–80.

    Article  PubMed  Google Scholar 

  54. Williamson PD, Boon PA, Thadani VM, Darcey TM, Spencer DD, Spencer SS, et al. Parietal lobe epilepsy: diagnostic considerations and results of surgery. Ann Neurol. 1992;31(2):193–201.

    Article  PubMed  CAS  Google Scholar 

  55. Sveinbjornsdottir S, Duncan JS. Parietal and occipital lobe epilepsy: a review. Epilepsia. 1993;34(3):493–521.

    Article  PubMed  CAS  Google Scholar 

  56. Dewhurst K, Pearson J. Visual hallucinations of the self in organic disease. J Neurol Neurosurg Psychiatry. 1955;18(1):53–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Ionasescu V. Paroxysmal disorders of the body image in temporal lobe epilepsy. Acta Psychiatr Scand. 1960;35:171–81.

    Article  PubMed  CAS  Google Scholar 

  58. Fish DR, Gloor P, Quesney FL, Olivier A. Clinical responses to electrical brain stimulation of the temporal and frontal lobes in patients with epilepsy. Pathophysiological implications. Brain. 1993;116(Pt 2):397–414.

    Article  PubMed  Google Scholar 

  59. Caplan JP, Epstein LA, Stern TA. Consultants’ conflicts: a case discussion of differences and their resolution. Psychosomatics. 2008;49(1):8–13.

    Article  PubMed  Google Scholar 

  60. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094–120.

    Article  PubMed  Google Scholar 

  61. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Washington, DC: APA; 2013.

    Book  Google Scholar 

  62. Holden B, Gitlesen JP. The association between severity of intellectual disability and psychiatric symptomatology. J Intellect Disabil Res. 2004;48(Pt 6):556–62.

    Article  PubMed  CAS  Google Scholar 

  63. Santosh PJ, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. Lancet. 1999;354(9174):233–42.

    Article  PubMed  CAS  Google Scholar 

  64. Cooper SA, Smiley E, Morrison J, Allan L, Williamson A, Finlayson J, et al. Psychosis and adults with intellectual disabilities. Prevalence, incidence, and related factors. Soc Psychiatry Psychiatr Epidemiol. 2007;42(7):530–6.

    Article  PubMed  Google Scholar 

  65. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry. 1999;56(10):940–5.

    Article  PubMed  CAS  Google Scholar 

  66. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.

    Article  PubMed  Google Scholar 

  67. Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.

    Article  PubMed  Google Scholar 

  68. Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer’s disease: review of the brain decade. Psychosomatics. 2003;44(5):388–401.

    Article  PubMed  Google Scholar 

  69. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162(11):2022–30.

    Article  PubMed  Google Scholar 

  70. Burghaus L, Eggers C, Timmermann L, Fink GR, Diederich NJ. Hallucinations in neurodegenerative diseases. CNS Neurosci Ther. 2012;18(2):149–59.

    Article  PubMed  CAS  Google Scholar 

  71. Matsumoto N, Ikeda M, Fukuhara R, Shinagawa S, Ishikawa T, Mori T, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord. 2007;23(4):219–24.

    Article  PubMed  Google Scholar 

  72. Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA. Psychosis in Alzheimer’s disease. Biol Psychiatry. 2014;75(7):542–52.

    Article  PubMed  Google Scholar 

  73. Farber NB, Rubin EH, Newcomer JW, Kinscherf DA, Miller JP, Morris JC, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry. 2000;57(12):1165–73.

    Article  PubMed  CAS  Google Scholar 

  74. Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002;58(6):907–11.

    Article  PubMed  CAS  Google Scholar 

  75. Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, et al. Genome-wide association study of Alzheimer’s disease with psychotic symptoms. Mol Psychiatry. 2012;17(12):1316–27.

    Article  PubMed  CAS  Google Scholar 

  76. Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, et al. Psychosis and aggression in Alzheimer’s disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71(6):777–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol. 1998;55(10):1335–40.

    Article  PubMed  CAS  Google Scholar 

  78. Hamilton RL. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10(3):378–84.

    Article  PubMed  CAS  Google Scholar 

  79. Murray PS, Kirkwood CM, Gray MC, Fish KN, Ikonomovic MD, Hamilton RL, et al. Hyperphosphorylated tau is elevated in Alzheimer’s disease with psychosis. J Alzheimers Dis. 2014;39(4):759–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Mendez MF, Lauterbach EC, Sampson SM, ANPA Committee on Research. An evidence-based review of the psychopathology of frontotemporal dementia: a report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci. 2008;20(2):130–49.

    Article  PubMed  Google Scholar 

  81. Blanc F, Noblet V, Philippi N, Cretin B, Foucher J, Armspach JP, et al. Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases. PLoS One. 2014;9(12):e114774.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Lai MK, Lai OF, Keene J, Esiri MM, Francis PT, Hope T, et al. Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex. Neurology. 2001;57(5):805–11.

    Article  PubMed  CAS  Google Scholar 

  83. Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170–8.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Josephs KA, Whitwell JL, Boeve BF, Knopman DS, Tang-Wai DF, Drubach DA, et al. Visual hallucinations in posterior cortical atrophy. Arch Neurol. 2006;63(10):1427–32.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Suarez-Gonzalez A, Crutch SJ, Franco-Macias E, Gil-Neciga E. Neuropsychiatric symptoms in posterior cortical atrophy and Alzheimer disease. J Geriatr Psychiatry Neurol. 2016;29(2):65–71.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38(5):553–63.

    Article  PubMed  CAS  Google Scholar 

  87. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.

    Article  PubMed  Google Scholar 

  88. Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin. 1996;14(2):317–35.

    Article  PubMed  CAS  Google Scholar 

  89. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Cummings JL. Behavioral complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc. 1991;39(7):708–16.

    Article  PubMed  CAS  Google Scholar 

  91. Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63(4):434–40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996;53(12):1265–8.

    Article  PubMed  CAS  Google Scholar 

  93. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733–45.

    Article  PubMed  Google Scholar 

  94. Asaad G, Shapiro B. Hallucinations: theoretical and clinical overview. Am J Psychiatry. 1986;143(9):1088–97.

    Article  PubMed  CAS  Google Scholar 

  95. Fenelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson’s disease. J Neurol. 2002;249(12):1699–703.

    Article  PubMed  Google Scholar 

  96. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;64(4):533–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Henderson MJ, Mellers JDC. Psychosis in Parkinson’s disease: ‘between a rock and a hard place’. Int Rev Psychiatry. 2000;12(4):319–34.

    Article  Google Scholar 

  98. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006;66(1):93–8.

    Article  PubMed  Google Scholar 

  99. Shergill SS, Murray RM, McGuire PK. Auditory hallucinations: a review of psychological treatments. Schizophr Res. 1998;32(3):137–50.

    Article  PubMed  CAS  Google Scholar 

  100. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55(7):969–78.

    Article  PubMed  CAS  Google Scholar 

  101. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson’s disease. Neurology. 1993;43(12 Suppl 6):S47–52.

    PubMed  CAS  Google Scholar 

  102. Auzou P, Ozsancak C, Hannequin D, Moore N, Augustin P. Clozapine for the treatment of psychosis in Parkinson’s disease: a review. Acta Neurol Scand. 1996;94(5):329–36.

    Article  PubMed  CAS  Google Scholar 

  103. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340(10):757–63.

    Article  Google Scholar 

  104. de la Chapelle A, Kari C, Nurminen M, Hernberg S. Clozapine-induced agranulocytosis. A genetic and epidemiologic study. Hum Genet. 1977;37(2):183–94.

    Article  PubMed  Google Scholar 

  105. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996;47(4):1085–7.

    Article  PubMed  CAS  Google Scholar 

  106. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002;52(5):438–45.

    Article  PubMed  CAS  Google Scholar 

  107. Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology. 1998;50(4):1195–6.

    Article  PubMed  CAS  Google Scholar 

  108. Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson’s disease patients: results of an open label pilot study. Clin Neuropharmacol. 1998;21(5):285–8.

    PubMed  CAS  Google Scholar 

  109. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17(5):1031–5.

    Article  PubMed  Google Scholar 

  110. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995;56(12):556–9.

    PubMed  CAS  Google Scholar 

  111. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2000;12(3):364–9.

    Article  PubMed  CAS  Google Scholar 

  112. Workman RH Jr, Orengo CA, Bakey AA, Molinari VA, Kunik ME. The use of risperidone for psychosis and agitation in demented patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1997;9(4):594–7.

    Article  PubMed  CAS  Google Scholar 

  113. Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov Disord. 2000;15(6):1230–7.

    Article  PubMed  CAS  Google Scholar 

  114. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20(8):958–63.

    Article  PubMed  Google Scholar 

  115. Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol. 2006;29(4):215–9.

    Article  PubMed  CAS  Google Scholar 

  116. Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol. 2006;253(2):171–5.

    Article  PubMed  CAS  Google Scholar 

  117. Dewey RB Jr, O’Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology. 2000;55(11):1753–4.

    Article  PubMed  Google Scholar 

  118. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology. 1995;12(1):39–45.

    PubMed  CAS  Google Scholar 

  119. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67(4):416–21.

    Article  PubMed  Google Scholar 

  120. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35(4):881–92.

    Article  PubMed  CAS  Google Scholar 

  121. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1985;48(5):413–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  122. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006;253(2):242–7.

    Article  PubMed  CAS  Google Scholar 

  123. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21(11):1899–907.

    Article  PubMed  Google Scholar 

  124. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–18.

    Article  PubMed  CAS  Google Scholar 

  125. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708–12.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  126. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34(6):561–6.

    Article  PubMed  Google Scholar 

  128. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.

    Article  PubMed  PubMed Central  Google Scholar 

  129. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med. 1992;22(4):911–22.

    Article  PubMed  CAS  Google Scholar 

  130. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology. 1996;47(5):1148–52.

    Article  PubMed  CAS  Google Scholar 

  131. Ballard C, Holmes C, McKeith I, Neill D, O'Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry. 1999;156(7):1039–45.

    PubMed  CAS  Google Scholar 

  132. Rockwell E, Choure J, Galasko D, Olichney J, Jeste DV. Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses. Int J Geriatr Psychiatry. 2000;15(9):819–23.

    Article  PubMed  CAS  Google Scholar 

  133. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.

    Article  PubMed  CAS  Google Scholar 

  134. Ferman TJ, Boeve BF. Dementia with Lewy bodies. Neurol Clin. 2007;25(3):741–60, vii

    Article  PubMed  PubMed Central  Google Scholar 

  135. Ferman TJ, Boeve BF, Smith GE, Silber MH, Lucas JA, Graff-Radford NR, et al. Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations. J Int Neuropsychol Soc. 2002;8(7):907–14.

    Article  PubMed  Google Scholar 

  136. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(Pt 2):391–403.

    Article  PubMed  CAS  Google Scholar 

  137. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001;56(5):643–9.

    Article  PubMed  CAS  Google Scholar 

  138. Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease. Ann N Y Acad Sci. 1991;640:197–202.

    Article  PubMed  CAS  Google Scholar 

  139. McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2004;18(1):94–100.

    Article  PubMed  CAS  Google Scholar 

  140. Mori E, Ikeda M, Kosaka K, Donepezil DLB, Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41–52.

    Article  PubMed  CAS  Google Scholar 

  141. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–6.

    Article  PubMed  CAS  Google Scholar 

  142. Aarsland D, Perry R, Larsen JP, McKeith IG, O’Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633–7.

    Article  PubMed  Google Scholar 

  143. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  144. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(3):549–53.

    Article  PubMed  CAS  Google Scholar 

  145. Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother. 2003;4(11):2027–37.

    Article  PubMed  CAS  Google Scholar 

  146. Terao T, Shimomura T, Izumi Y, Nakamura J. Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies. J Clin Psychiatry. 2003;64(12):1520–1.

    Article  PubMed  Google Scholar 

  147. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13(2):67–73.

    Article  PubMed  CAS  Google Scholar 

  148. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8.

    Article  PubMed  CAS  Google Scholar 

  149. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.

    Article  PubMed  CAS  Google Scholar 

  150. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77.

    Article  PubMed  PubMed Central  Google Scholar 

  151. Tartaglia MC, Kertesz A, Ang LC. Delusions and hallucinations in frontotemporal dementia: a clinicopathologic case report. Cogn Behav Neurol. 2008;21(2):107–10.

    Article  PubMed  Google Scholar 

  152. Shinagawa S, Naasan G, Karydas AM, Coppola G, Pribadi M, Seeley WW, et al. Clinicopathological study of patients with C9ORF72-associated frontotemporal dementia presenting with delusions. J Geriatr Psychiatry Neurol. 2015;28(2):99–107.

    Article  PubMed  Google Scholar 

  153. Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, Puel M, et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat. 2007;28(9):846–55.

    Article  PubMed  CAS  Google Scholar 

  154. Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A, et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 2010;120(1):33–41.

    Article  PubMed  PubMed Central  Google Scholar 

  155. Shinagawa S, Nakajima S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K, et al. Psychosis in frontotemporal dementia. J Alzheimers Dis. 2014;42(2):485–99.

    Article  PubMed  Google Scholar 

  156. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58(5):212–6.

    Article  PubMed  CAS  Google Scholar 

  157. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49(1):13–9.

    Article  PubMed  CAS  Google Scholar 

  158. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172(4):400–8.

    Article  CAS  Google Scholar 

  159. Haywood AM. Transmissible spongiform encephalopathies. N Engl J Med. 1997;337(25):1821–8.

    Article  PubMed  CAS  Google Scholar 

  160. Rabinovici GD, Wang PN, Levin J, Cook L, Pravdin M, Davis J, et al. First symptom in sporadic Creutzfeldt-Jakob disease. Neurology. 2006;66(2):286–7.

    Article  PubMed  CAS  Google Scholar 

  161. Heinz A, Schmidt LG, Winterer G, Gerhard L, Przuntek H. Optical and tactile hallucinosis as clinical onset of Creutzfeld-Jakob disease. Nervenarzt. 1995;66(9):712–6.

    PubMed  CAS  Google Scholar 

  162. Lueck CJ, McIlwaine GG, Zeidler M. Creutzfeldt-Jakob disease and the eye. II. Ophthalmic and neuro-ophthalmic features. Eye (Lond). 2000;14(Pt 3A):291–301.

    Article  Google Scholar 

  163. Lueck CJ, McIlwaine GG, Zeidler M. Creutzfeldt-Jakob disease and the eye. I. Background and patient management. Eye (Lond). 2000;14(Pt 3A):263–90.

    Article  Google Scholar 

  164. Baiardi S, Capellari S, Ladogana A, Strumia S, Santangelo M, Pocchiari M, et al. Revisiting the Heidenhain variant of Creutzfeldt-Jakob disease: evidence for prion type variability influencing clinical course and laboratory findings. J Alzheimers Dis. 2016;50(2):465–76.

    Article  PubMed  CAS  Google Scholar 

  165. Appleby BS, Appleby KK, Crain BJ, Onyike CU, Wallin MT, Rabins PV. Characteristics of established and proposed sporadic Creutzfeldt-Jakob disease variants. Arch Neurol. 2009;66(2):208–15.

    Article  PubMed  Google Scholar 

  166. Brar HK, Vaddigiri V, Scicutella A. Of illusions, hallucinations and Creutzfeldt-Jakob disease (Heidenhain’s variant). J Neuropsychiatry Clin Neurosci. 2005;17(1):124–6.

    Article  PubMed  Google Scholar 

  167. Kropp S, Schulz-Schaeffer WJ, Finkenstaedt M, Riedemann C, Windl O, Steinhoff BJ, et al. The Heidenhain variant of Creutzfeldt-Jakob disease. Arch Neurol. 1999;56(1):55–61.

    Article  PubMed  CAS  Google Scholar 

  168. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347(9006):921–5.

    Article  PubMed  CAS  Google Scholar 

  169. Collinge J. Variant Creutzfeldt-Jakob disease. Lancet. 1999;354(9175):317–23.

    Article  PubMed  CAS  Google Scholar 

  170. Henry C, Knight R. Clinical features of variant Creutzfeldt-Jakob disease. Rev Med Virol. 2002;12(3):143–50.

    Article  PubMed  Google Scholar 

  171. Spencer MD, Knight RS, Will RG. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. BMJ. 2002;324(7352):1479–82.

    Article  PubMed  PubMed Central  Google Scholar 

  172. Zeidler M, Johnstone EC, Bamber RW, Dickens CM, Fisher CJ, Francis AF, et al. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet. 1997;350(9082):908–10.

    Article  PubMed  CAS  Google Scholar 

  173. Forloni G, Artuso V, Roiter I, Morbin M, Tagliavini F. Therapy in prion diseases. Curr Top Med Chem. 2013;13(19):2465–76.

    Article  PubMed  CAS  Google Scholar 

  174. Brown TM, Boyle MF. Delirium. BMJ. 2002;325(7365):644–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  175. Miller MO. Evaluation and management of delirium in hospitalized older patients. Am Fam Physician. 2008;78(11):1265–70.

    PubMed  Google Scholar 

  176. Jesse S, Brathen G, Ferrara M, Keindl M, Ben-Menachem E, Tanasescu R, et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand. 2017;135(1):4–16.

    Article  PubMed  CAS  Google Scholar 

  177. Mirijello A, D’Angelo C, Ferrulli A, Vassallo G, Antonelli M, Caputo F, et al. Identification and management of alcohol withdrawal syndrome. Drugs. 2015;75(4):353–65.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  178. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481–94.

    Article  PubMed  Google Scholar 

  179. Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e280.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  181. Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241–55.

    Article  PubMed  Google Scholar 

  182. Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun. 2014;48-49:10–3.

    Article  PubMed  CAS  Google Scholar 

  183. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol. 1992;19(1):47–52.

    PubMed  CAS  Google Scholar 

  184. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology. 2007;69(7):644–54.

    Article  PubMed  Google Scholar 

  185. Hanly JG. Neuropsychiatric lupus. Rheum Dis Clin North Am. 2005;31(2):273–98. vi

    Article  PubMed  Google Scholar 

  186. Paholpak P, Rangseekajee P, Foocharoen C. Characteristics, treatments and outcome of psychosis in Thai SLE patients. J Psychosom Res. 2012;73(6):448–51.

    Article  PubMed  Google Scholar 

  187. Chang HC, Liu CM, Huang WL, Liao SC, Liou MJ, Chang LR. Psychosis and brain hypoperfusion in remitted phase of systemic lupus erythematosus. Psychiatry Clin Neurosci. 2012;66(6):535–6.

    Article  PubMed  Google Scholar 

  188. Govoni M, Castellino G, Padovan M, Borrelli M, Trotta F. Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus. Lupus. 2004;13(3):149–58.

    Article  PubMed  CAS  Google Scholar 

  189. Bonfa E, Chu JL, Brot N, Elkon KB. Lupus anti-ribosomal P peptide antibodies show limited heterogeneity and are predominantly of the IgG1 and IgG2 subclasses. Clin Immunol Immunopathol. 1987;45(1):129–38.

    Article  PubMed  CAS  Google Scholar 

  190. Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 1981;70(2):240–6.

    Article  PubMed  CAS  Google Scholar 

  191. Bhangle SD, Kramer N, Rosenstein ED. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int. 2013;33(8):1923–32.

    Article  PubMed  CAS  Google Scholar 

  192. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med. 1991;81(296):975–84.

    Article  PubMed  CAS  Google Scholar 

  193. Ferracci F, Carnevale A. The neurological disorder associated with thyroid autoimmunity. J Neurol. 2006;253(8):975–84.

    Article  PubMed  CAS  Google Scholar 

  194. Zhou JY, Xu B, Lopes J, Blamoun J, Li L. Hashimoto encephalopathy: literature review. Acta Neurol Scand. 2017;135(3):285–90.

    Article  PubMed  CAS  Google Scholar 

  195. Zouboulis CC, Vaiopoulos G, Marcomichelakis N, Palimeris G, Markidou I, Thouas B, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behcet’s disease in Greece. Clin Exp Rheumatol. 2003;21(4 Suppl 30):S19–26.

    PubMed  CAS  Google Scholar 

  196. Al-Araji A, Kidd DP. Neuro-Behcet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.

    Article  PubMed  Google Scholar 

  197. Deniz O, Caykoylu A, Vural G, Albayrak Y, Temel S, Aydin I, et al. A case study of neuro-psycho-Behcet’s syndrome presenting with psychotic attack. Clin Neurol Neurosurg. 2009;111(10):877–9.

    Article  PubMed  Google Scholar 

  198. Conde-Sendin MA, Amela-Peris R, Aladro-Benito Y, Maroto AA. Current clinical spectrum of neurosyphilis in immunocompetent patients. Eur Neurol. 2004;52(1):29–35.

    Article  PubMed  Google Scholar 

  199. Vargas AP, Carod-Artal FJ, Del Negro MC, Rodrigues MP. [Dementia caused by neurosyphilis: clinical and neuropsychological follow-up of a patient]. Arq Neuropsiquiatr. 2000;58(2B):578–82.

    Google Scholar 

  200. Taycan O, Ugur M, Ozmen M. Quetiapine vs. risperidone in treating psychosis in neurosyphilis: a case report. Gen Hosp Psychiatry. 2006;28(4):359–61.

    Article  PubMed  Google Scholar 

  201. Crozatti LL, de Brito MH, Lopes BN, de Campos FP. Atypical behavioral and psychiatric symptoms: neurosyphilis should always be considered. Autops Case Rep. 2015;5(3):43–7.

    Article  PubMed  PubMed Central  Google Scholar 

  202. Kinson RM, Chan LG. Psychiatric symptoms as the sole manifestation of neurosyphilis. J Neuropsychiatry Clin Neurosci. 2013;25(4):E39–40.

    Article  PubMed  Google Scholar 

  203. Noblett J, Roberts E. The importance of not jumping to conclusions: syphilis as an organic cause of neurological, psychiatric and endocrine presentations. BMJ Case Rep. 2015;2015.

    Google Scholar 

  204. Kambe T, Shimura H, Ueno Y, Nishioka K, Tanaka R, Hattori N, et al. Vivid visual hallucinations manifested as the initial symptom in a patient with neurosyphilis. Psychosomatics. 2013;54(3):284–5.

    Article  PubMed  Google Scholar 

  205. Turan S, Emul M, Duran A, Mert A, Ugur M. Effectiveness of olanzapine in neurosyphilis related organic psychosis: a case report. J Psychopharmacol. 2007;21(5):556–8.

    Article  PubMed  Google Scholar 

  206. Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis. 2007;30(5):631–41.

    Article  PubMed  CAS  Google Scholar 

  207. DiMagno EP, Lowe JE, Snodgrass PJ, Jones JD. Ornithine transcarbamylase deficiency—a cause of bizarre behavior in a man. N Engl J Med. 1986;315(12):744–7.

    Article  PubMed  CAS  Google Scholar 

  208. Enns GM, O’Brien WE, Kobayashi K, Shinzawa H, Pellegrino JE. Postpartum “psychosis” in mild argininosuccinate synthetase deficiency. Obstet Gynecol. 2005;105(5 Pt 2):1244–6.

    Article  PubMed  Google Scholar 

  209. Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homocystinuria and “schizophrenia”. A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity. N Engl J Med. 1975;292(10):491–6.

    Article  PubMed  CAS  Google Scholar 

  210. Pasquier F, Lebert F, Petit H, Zittoun J, Marquet J. Methylenetetrahydrofolate reductase deficiency revealed by a neuropathy in a psychotic adult. J Neurol Neurosurg Psychiatry. 1994;57(6):765–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  211. Roze E, Gervais D, Demeret S, Ogier de Baulny H, Zittoun J, Benoist JF, et al. Neuropsychiatric disturbances in presumed late-onset cobalamin C disease. Arch Neurol. 2003;60(10):1457–62.

    Article  PubMed  Google Scholar 

  212. Rauschka H, Colsch B, Baumann N, Wevers R, Schmidbauer M, Krammer M, et al. Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. Neurology. 2006;67(5):859–63.

    Article  PubMed  CAS  Google Scholar 

  213. Baumann N, Masson M, Carreau V, Lefevre M, Herschkowitz N, Turpin JC. Adult forms of metachromatic leukodystrophy: clinical and biochemical approach. Dev Neurosci. 1991;13(4-5):211–5.

    Article  PubMed  CAS  Google Scholar 

  214. Navon R. Molecular and clinical heterogeneity of adult GM2 gangliosidosis. Dev Neurosci. 1991;13(4-5):295–8.

    Article  PubMed  CAS  Google Scholar 

  215. Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med. 2005;7(2):119–23.

    Article  PubMed  CAS  Google Scholar 

  216. Hurowitz GI, Silver JM, Brin MF, Williams DT, Johnson WG. Neuropsychiatric aspects of adult-onset Tay-Sachs disease: two case reports with several new findings. J Neuropsychiatry Clin Neurosci. 1993;5(1):30–6.

    Article  PubMed  CAS  Google Scholar 

  217. Sevin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, Vanier MT, et al. The adult form of Niemann-Pick disease type C. Brain. 2007;130(Pt 1):120–33.

    PubMed  Google Scholar 

  218. Gutschalk A, Harting I, Cantz M, Springer C, Rohrschneider K, Meinck HM. Adult alpha-mannosidosis: clinical progression in the absence of demyelination. Neurology. 2004;63(9):1744–6.

    Article  PubMed  CAS  Google Scholar 

  219. Malm D, Pantel J, Linaker OM. Psychiatric symptoms in alpha-mannosidosis. J Intellect Disabil Res. 2005;49(Pt 11):865–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Centro Dino Ferrari, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

    Alessio Di Fonzo & Edoardo Monfrini

  2. Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino Ferrari, University of Milan, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Paola Basilico & Andrea Arighi

Authors
  1. Alessio Di Fonzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edoardo Monfrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Basilico
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Arighi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessio Di Fonzo .

Editor information

Editors and Affiliations

  1. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

    Paolo Brambilla

  2. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

    Massimo Carlo Mauri

  3. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

    Alfredo Carlo Altamura

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Di Fonzo, A., Monfrini, E., Basilico, P., Arighi, A. (2018). Hallucinations in Neurological Disorders. In: Brambilla, P., Mauri, M., Altamura, A. (eds) Hallucinations in Psychoses and Affective Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-75124-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-75124-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-75123-8

  • Online ISBN: 978-3-319-75124-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation